Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Catabasis Pharmaceuticals Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Catabasis Pharmaceuticals Inc since year 2005.
Table 2 shows the detailed insider transactions of Catabasis Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is CATB. The reporting company's CIK number is 1454789.
The total value of stock buying since 2005 is $22,201,608.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2015-06-30||Laufer Ron (Director)||Buy||223,439||12.00||2,681,268|
|2015-06-30||Sv Life Sciences Fund V Strategic Partners, L.p. (10% Owner)||Buy||391,090||12.00||4,693,080|
|2015-06-30||Clarus Ventures Ii, Llc (10% Owner)||Buy||376,695||12.00||4,520,340|
|2015-06-30||Medimmune Ventures, Inc. (10% Owner)||Buy||223,439||12.00||2,681,268|
|2015-06-30||George Jean (Director)||Buy||258,776||12.00||3,105,312|
|2015-06-30||Galakatos Nicholas (Director)||Buy||376,695||12.00||4,520,340|
Insider trading activities including stock purchases, stock sales, and option exercises of CATB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Catabasis Pharmaceuticals Inc (symbol CATB, CIK number 1454789) see the Securities and Exchange Commission (SEC) website.